Open Access

Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer

KASHIWAGI SHINICHIRO 1
ASANO YUKA 1
TAKADA KOJI 1
GOTO WATARU 1
KOUHASHI RIKA 1
YABUMOTO AKIMICHI 1
TAUCHI YUKIE 1
MORISAKI TAMAMI 1
OGISAWA KANA 1
SHIBUTANI MASATSUNE 2
TANAKA HIROAKI 2
  &  
OHIRA MASAICHI 1 2

1Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

2Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

Cancer Diagnosis & Prognosis Jul-Aug; 2(4): 443-451 DOI: 10.21873/cdp.10127
Received 14 March 2022 | Revised 13 July 2024 | Accepted 16 May 2022
Corresponding author
Shinichiro Kashiwagi, MD, Ph.D., Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-Ku, Osaka 545- 8585, Japan. Tel: +81 666453838, Fax: +81 666466450 kashiwa@med.osaka-cu.ac.jp

Abstract

Background/Aim: Tumor microenvironment (TME) assessment is considered to play an important role in the prediction of prognosis and therapeutic response following breast cancer treatment. No consensus has been reached regarding evaluation methods despite reports on the utilization of tumor-infiltrating lymphocytes (TILs) for immune TME (iTME) monitoring. Optimum timing of iTME assessment has not yet been established. Patients and Methods: Two hundred thirty-nine patients were treated with neoadjuvant chemotherapy (NAC). During the period from diagnostic needle biopsy to NAC initiation for breast cancer, the optimal evaluation timing was examined using a receiver operating characteristic (ROC) curve analysis. Results: A significant correlation between TILs and pathological complete response (pCR) was only observed in the short-term group (≤35 days) (p=0.033). Prognostic analysis revealed that in the short-term group, patients with high TIL levels had a significantly better survival prognosis relative to those with low TIL levels (>35 days) [disease-free survival (DFS): p=0.001, overall survival (OS): p=0.021]. TILs were identified as an independent factor affecting DFS in a multivariate analysis (p=0.008, hazard ratio=0.130). Conclusion: TIL assessment during NAC for breast cancer is a prognostic predictor only when performed at ≤35 days before NAC initiation.
Keywords: tumor microenvironment, breast cancer, immune response, neoadjuvant chemotherapy, tumor-infiltrating lymphocytes, prognostic marker

Cancers not only directly affect the tumor cells, but also influence the local microenvironment (e.g., surrounding stromal cells and blood vessels) to enhance tumor cell survival. Accordingly, tumor tissues include not only cancer cells, but also inflammatory cells, immune cells, component cells of blood vessels and lymphatic vessels, fibroblasts, and fibrous tissues, which create the characteristic tumor microenvironment (TME) (1). Regarding cancer treatment, evaluation of the host TME has been considered to play an important role in the prediction of prognosis and therapeutic effects (2). Furthermore, the immune system within the host TME has been noted as immune TME (iTME). Furthermore, the strategy of treatment related to iTME may be a key factor in the future development of cancer therapies (3-5). Previous reports have described the use of tumor-infiltrating lymphocytes (TILs) in various carcinomas, including breast cancer, for monitoring the iTME (4,6-11). However, a consensus regarding the iTME assessment method has not been reached (12). Identification of the optimal region and timing for TIL assessment will facilitate the design of optimal treatment options based on accurate iTME monitoring.

TIL is a generic designation for the lymphocytes that accumulate within tumors, and the in situ expression status of these cells is thought to play an important role in tumor-associated immune mechanisms. In breast cancer, the in situ expression status of TILs was found to be useful for predicting prognosis and chemotherapeutic effects (6,13-15). Therefore, an assessment of the TIL expression is important and must be done simply and reproducibly. Regarding the optimal region of TIL evaluation, the International Working Group currently recommends the tumor stroma (12). However, the iTME exhibits dynamic changes, and the timing of the assessment has not yet been optimized. Therefore, in this study, we evaluated and clinically verified the timing of assessment for predicting therapeutic effects to neoadjuvant chemotherapy (NAC), using TILs as an indicator.

Patients and Methods

Patient background. This is a retrospective analysis based on archival tissue samples. A total of 239 patients with resectable early-stage breast cancer received NAC between 2007 and 2015 at Osaka City University Hospital, Osaka, Japan. Patients were diagnosed with stage IIA (T1, N1, M0 or T2, N0, M0), IIB (T2, N1, M0 or T3, N0, M0), or IIIA disease (T1-2, N2, M0 or T3, N1-2, M0). Qualitative breast cancer diagnoses were confirmed histologically by core needle biopsy (CNB) or vacuum-assisted biopsy (VAB). Breast cancer stage stratification was based on the TNM Classification of Malignant tumors, Union for International Cancer Control (UICC), Seventh Edition (16). Breast cancer subtypes were classified through an immunohistochemical evaluation of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor (HER) 2, and Ki67 expression, as follows: luminal A, ER+ and/or PgR+, HER2-, Ki67-low; luminal B, ER+ and/or PgR+, HER2+ or ER+ and/or PgR+, HER2-, Ki67-high; HER2-enriched (HER2BC), ER–, PgR–, and HER2+; and triple-negative breast cancer (TNBC), negative for ER, PgR and HER2 (17). A Ki67-labeling index was considered positive with ≥14% of tumor cells with nuclear staining (17).

All patients received NAC per a standardized protocol. The following regimen was administered: four courses of FEC100 (500 mg/m2 fluorouracil, 100 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m2 paclitaxel administered weekly (18-20). Patients with HER2-positive breast cancer additionally received weekly (2 mg/kg) or tri-weekly (6 mg/kg) trastuzumab therapy (21).

Patients underwent mastectomy or breast-conserving surgery following NAC (22). The anti-tumor effects of NAC were assessed in accordance with the Response Evaluation Criteria in Solid tumors (RECIST) (23). A pathological complete response (pCR) was defined as an absence of residual invasive carcinoma in both the breast and lymph nodes of surgically resected specimens, regardless of residual intraductal carcinoma (24). Patients who underwent breast-conserving mastectomy were administered adjuvant radiotherapy to the residual breast. Standard postoperative adjuvant therapy was administered according to the breast cancer subtype.

Disease-free survival (DFS) was defined as the period from the initiation of NAC to the occurrence of any local, locoregional, and/or distant recurrence or death from any cause. Overall survival (OS) was defined as the period from the initiation of NAC to the time of death from any cause. The median follow-up periods were 3.4 years (range=0.1-6.0 years) for DFS and 3.7 years (range=0.1-6.0 years) for OS.

Immunohistochemistry. Immunohistochemical staining for ER, PgR, HER2, and Ki-67 was performed on formalin-fixed, paraffin-embedded tumor tissues obtained before and after chemotherapy. Primary monoclonal antibodies directed against ER (clone 1D5, dilution 1:80; Dako, Cambridge, UK), PgR (clone PgR636, dilution 1:100; Dako), HER2 (HercepTest™; Dako), and Ki67 (clone MIB-1, dilution 1:00; Dako) were used. The cut-off values for ER and PgR positivity were set at 1%. HER2 status was evaluated according to the ASCO/CAP HER2 Test Guideline Recommendations (25). Briefly, breast cancers were defined as HER2 positive with an immunohistochemical score of 3+, or 2+ with HER2 gene amplification indicated by fluorescence in situ hybridization.

Region of histopathological TIL evaluation. A histopathological assessment of predictive factors was performed using biopsy specimens collected at the time of breast cancer diagnosis. The optimal region for TIL assessment was selected according to the recommendations of the International Working Group (12). Specifically, TILs were measured by examining the occupation ratio of immune cells present in the tumor stroma of hematoxylin and eosin (HE) stained specimens at 400× magnification (9,26). Necrotic tissue and surrounding normal tissues were not included in the evaluation region. Proportional scores of 3, 2, 1, and 0 were given if the area of stroma containing lymphoplasmacytic infiltration around invasive tumor cell nests comprised >50%, >10-50%, ≤10%, and 0%, respectively (Figure 1). A score of ≥2 was considered positive for TILs, whereas scores of 1 and 0 were considered negative. Two pathologists evaluated the TILs independently and were blinded to the patient information. If the evaluations were discordant, the slides were reviewed, and a final score was reached by consensus.

Timing of histopathological evaluation of TILs. The time of biopsy for the diagnosis of breast cancer and the time of NAC initiation were set as the start and end points, respectively. The interval between the start and end points was calculated, and a receiver operating characteristic (ROC) curve for DFS was used to determine a cut-off value of 35 days as the optimum timing of assessment. This cut-off value was used to assign subjects to either a short-term (≤35 days) or long-term group (>35 days). We compared prognosis between the groups and conducted clinicopathological background and prognostic analyses based on the TIL expression status.

Statistical analysis. We used the SPSS version 19.0 statistical software package (IBM, Armonk, NY, USA) for all statistical analyses. Associations between the TILs and clinicopathological variables were examined using the chi square or Fisher’s exact test. The Cox proportional hazards model was used to compute univariate and multivariate hazard ratios (HR) with 95% confidence intervals (CIs) for the study parameters, and a backward stepwise method was used for variable selection in the multivariate analyses. DFS and OS were estimated using the Kaplan–Meier method and compared using the log-rank test. Differences were considered statistically significant at p-values of <0.05.

Results

Prognostic analysis of the long-term and short-term patient groups. Regarding TIL evaluation, the mean interval from the time of biopsy for breast cancer diagnosis to the start of NAC was 39 days (median: 35 days, range=13-98 days). As noted above, the ROC curve analysis of DFS yielded a cut-off value of 35 days (sensitivity: 57.4%, specificity: 38.5%, area under the curve (AUC): 0.592, p=0.050, 95%CI=0.500-0.685), and used to stratify patients into short-term (≤35 days) and long-term groups (>35 days) (Figure 2). Of the 239 NAC patients, 118 (49.4%) and 121 (50.6%) were classified into the short-term and long-term groups, respectively. DFS was significantly longer in the short-term group than the long-term group (p=0.020, log-rank) (Figure 3). OS was significantly longer in the short-term group than the long-term group (p=0.010, log-rank).

Prognostic analysis of the short-term and long-term groups based on TIL evaluation. We further confirmed the correlation between clinicopathological background factors and TILs. In the short-term group, 63 (53.4%) and 55 patients (46.6%) had high and low TIL expression statuses, respectively, whereas in the long-term group, 66 (54.5%) and 55 patients (45.5%) had high and low TIL expression statuses, respectively. In the short-term group, the pCR rate was higher among patients with high TIL expression (p=0.042), whereas no correlations with other factors were noted (Table I). By contrast, in the long-term group, no factors were found to correlate with the TIL expression status.

A prognostic analysis revealed that in the short-term group, those with high TIL levels had a significantly prolonged survival prognosis, compared to those with low TIL levels (p=0.001 and p=0.021, respectively; log-rank). In addition, no effect of TIL expression on the prognosis was observed in the long-term group (DFS: p=0.529, OS: p=0.457; log-rank) (Figure 4). TILs were also found to be a significant factor affecting DFS in the univariate analysis (p=0.004, HR=0.115), as well as an independent factor affecting DFS in a multivariate analysis (p=0.008, HR=0.130) (Table II) (Figure 5).

Discussion

Cancer cells were thought to proliferate autonomously and survive as a consequence of various genetic abnormalities; however, the surrounding environment (i.e., TME) has been found to greatly affect cancer cells and the formation of cancer-specific characteristics (27). Furthermore, the importance of iTME control has recently been recognized, as this factor affects not only the efficacy of immunotherapy, but also the efficacies and prognosis related to other treatments, such as anti-cancer chemotherapy (3,28). Various types of immune cell infiltration are observed in tumor tissues; however, the infiltration of immune suppressor cells [regulatory T cells (Tregs), myeloid derived suppressor cells (MDSCs), etc.] and production of immunosuppressive substances establishes immunosuppression and facilitates tumor immune escape (27,29).

Cancer immunoediting comprises three phases: the elimination phase (that is, cancer immune surveillance), equilibrium phase, and escape phase (29-33). Of these, the escape phase results from the ability of cancer cells to escape recognition and elimination by immune surveillance mechanisms, and thus represents the clinical manifestation of cancer (27). These escape mechanisms are thought to be effectively controlled by immune checkpoint inhibitors, and accordingly the utility of anti-PD-1 and anti-CTLA-4 antibodies, among others, have been demonstrated by large-scale clinical trials (33-35). Even in clinical practice, OS is extended in melanoma and lung cancer, and its effect is expected also in breast cancer. Clinical trials of anti-PD-1 and anti-PD-L1 antibodies are ongoing in breast cancer. In brief, the cancer immune response changes dynamically, and an understanding of the iTME, and particularly its strong immunosuppressive network, may be the key to future anticancer therapies.

When using TILs to evaluate the dynamically changing iTME, a standard optimum region and timing must be set. The TIL population exhibits intratissue heterogeneity, and therefore the TIL distribution and expression status must be evaluated in all specimens. Accordingly, the International Working Group has recommended the margin of the infiltrated part of the tumor stroma as the optimal region for assessment (12). As the iTME includes many Tregs and MDSCs with immunosuppressive activity, the tumor stroma appears to be suitable as an optimal evaluation region (36). However, the optimal timing for TILs remains uncertain. In the present study, we found that TILs were useful prognostic and pCR predictive biomarkers in patients for whom the interval from breast cancer diagnosis by biopsy to NAC initiation was short. These findings further support the consideration of optimum timing when utilizing TILs as a predictive marker of the therapeutic effects of NAC.

The iTME fluctuates dynamically along with cancer progression, leading to the concept of a cancer immunity cycle, which chronologically depicts the cancer-related immune response (37). First, as tumor antigens are released from tumor cells, antigen-presenting cells (APCs) such as dendritic cells take up and present these antigens on surface MHC molecules and migrate to the lymph nodes. Once in the lymph node, the APCs present the tumor antigens to T cells, leading to the activation of antigen-specific T cells. Subsequently, these activated T cells migrate to and invade tumor tissues. This latter step is observed during the assessment of TILs in situ. tumor cells that have been attacked and killed by T cells can also release new tumor antigens. The evaluation of TILs in situ may allow the observation of some steps in this cancer immunity cycle and facilitates monitoring of the iTME. Therefore, if the interval from biopsy to treatment initiation is short, it may be possible to determine the optimal timing for an accurate evaluation of TILs.

In the future, iTME evaluations are expected to play a key role in the development of individualized cancer treatments; however, whether an appropriate immune response can be evaluated using TILs remains an issue for future studies. Despite individual differences in the cancer immunologic conditions in human, the implementation of a clinically appropriate iTME monitoring using TILs would be expected to contribute to improvements in therapeutic effects and prognosis. However, the present study is limited by its retrospective design and the small number of subjects. A prospective review of therapeutic effects and prognosis in the context of an investigation of the optimal region and timing for TILs evaluation should be conducted in the future.

Conclusion

TIL assessment during NAC for breast cancer may be a useful prognostic factor only if the interval from biopsy to treatment initiation is short (≤35 days).

Conflicts of Interest

All of the Authors have no conflicts of interest to disclose regarding this study.

Authors’ Contributions

All Authors were involved in the preparation of this manuscript. SK collected the data and wrote the manuscript. SK, YA, KT, WG, RK, AY, YT, TM and KO performed the operation and designed the study. SK, MS, and HT summarized the data and revised the manuscript. MO provided a substantial contribution to the study design, performed the operation, and revised the manuscript. All Authors read and approved the final manuscript.

Acknowledgements

The Authors thank Tomomi Okawa (Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan) for the helpful advice regarding data management. This study was funded by grants from the Japan Society for the Promotion of Science (Tokyo, Japan) (KAKENHI, Nos. 20K08938, 26461957, and 17K10559) to Shinichiro Kashiwagi.

References

1 De Palma M Biziato D & Petrova TV Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 17(8) 457 - 474 2017. PMID: 28706266. DOI: 10.1038/nrc.2017.51
2 Allegrezza MJ & Conejo-Garcia JR Targeted therapy and immunosuppression in the tumor microenvironment. Trends Cancer. 3(1) 19 - 27 2017. PMID: 28718424. DOI: 10.1016/j.trecan.2016.11.009
3 Zitvogel L Kepp O & Kroemer G Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 8(3) 151 - 160 2011. PMID: 21364688. DOI: 10.1038/nrclinonc.2010.223
4 Fridman WH Pagès F Sautès-Fridman C & Galon J The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 12(4) 298 - 306 2012. PMID: 22419253. DOI: 10.1038/nrc3245
5 Couzin-Frankel J Breakthrough of the year 2013. Cancer immunotherapy. Science. 342(6165) 1432 - 1433 2013. PMID: 24357284. DOI: 10.1126/science.342.6165.1432
6 Savas P Salgado R Denkert C Sotiriou C Darcy PK Smyth MJ & Loi S Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 13(4) 228 - 241 2016. PMID: 26667975. DOI: 10.1038/nrclinonc.2015.215
7 Kocián P Šedivcová M Drgáč J Cerná K Hoch J Kodet R Bartůňková J Špíšek R & Fialová A Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. Hum Immunol. 72(11) 1022 - 1028 2011. PMID: 21884745. DOI: 10.1016/j.humimm.2011.07.312
8 Liu H Zhang T Ye J Li H Huang J Li X Wu B Huang X & Hou J Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother. 61(10) 1849 - 1856 2012. PMID: 22456757. DOI: 10.1007/s00262-012-1231-7
9 Mao Y Qu Q Zhang Y Liu J Chen X & Shen K The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 9(12) e115103 2014. PMID: 25501357. DOI: 10.1371/journal.pone.0115103
10 Luen SJ Savas P Fox SB Salgado R & Loi S Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 49(2) 141 - 155 2017. PMID: 28049579. DOI: 10.1016/j.pathol.2016.10.010
11 Luen SJ Salgado R Fox S Savas P Eng-Wong J Clark E Kiermaier A Swain SM Baselga J Michiels S & Loi S Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 18(1) 52 - 62 2017. PMID: 27964843. DOI: 10.1016/S1470-2045(16)30631-3
12 Salgado R Denkert C Demaria S Sirtaine N Klauschen F Pruneri G Wienert S Van den Eynden G Baehner FL Penault-Llorca F Perez EA Thompson EA Symmans WF Richardson AL Brock J Criscitiello C Bailey H Ignatiadis M Floris G Sparano J Kos Z Nielsen T Rimm DL Allison KH Reis-Filho JS Loibl S Sotiriou C Viale G Badve S Adams S Willard-Gallo K Loi S & International TILs Working Group 2014 The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 26(2) 259 - 271 2015. PMID: 25214542. DOI: 10.1093/annonc/mdu450
13 Miyashita M Sasano H Tamaki K Chan M Hirakawa H Suzuki A Tada H Watanabe G Nemoto N Nakagawa S Ishida T & Ohuchi N Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 148(3) 525 - 534 2014. PMID: 25395319. DOI: 10.1007/s10549-014-3197-y
14 Asano Y Kashiwagi S Goto W Kurata K Noda S Takashima T Onoda N Tanaka S Ohsawa M & Hirakawa K Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 103(7) 845 - 854 2016. PMID: 26953091. DOI: 10.1002/bjs.10127
15 Byrne A Savas P Sant S Li R Virassamy B Luen SJ Beavis PA Mackay LK Neeson PJ & Loi S Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat Rev Clin Oncol. 17(6) 341 - 348 2020. PMID: 32112054. DOI: 10.1038/s41571-020-0333-y
16 Greene FL & Sobin LH A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol. 99(5) 269 - 272 2009. PMID: 19170124. DOI: 10.1002/jso.21237
17 Goldhirsch A Wood WC Coates AS Gelber RD Thürlimann B Senn HJ & Panel members Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22(8) 1736 - 1747 2011. PMID: 21709140. DOI: 10.1093/annonc/mdr304
18 Mauri D Pavlidis N & Ioannidis JP Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 97(3) 188 - 194 2005. PMID: 15687361. DOI: 10.1093/jnci/dji021
19 Mieog JS van der Hage JA & van de Velde CJ Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. (2) CD005002 2007. PMID: 17443564. DOI: 10.1002/14651858.CD005002.pub2
20 Kawajiri H Takashima T Onoda N Kashiwagi S Noda S Ishikawa T Wakasa K & Hirakawa K Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer. Oncol Lett. 4(4) 612 - 616 2012. PMID: 23205071. DOI: 10.3892/ol.2012.801
21 Buzdar AU Valero V Ibrahim NK Francis D Broglio KR Theriault RL Pusztai L Green MC Singletary SE Hunt KK Sahin AA Esteva F Symmans WF Ewer MS Buchholz TA & Hortobagyi GN Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 13(1) 228 - 233 2007. PMID: 17200359. DOI: 10.1158/1078-0432.CCR-06-1345
22 Kashiwagi S Onoda N Asano Y Kurata K Morisaki T Noda S Kawajiri H Takashima T & Hirakawa K Partial mastectomy using manual blunt dissection (MBD) in early breast cancer. BMC Surg. 15 117 2015. PMID: 26494510. DOI: 10.1186/s12893-015-0102-5
23 Eisenhauer EA Therasse P Bogaerts J Schwartz LH Sargent D Ford R Dancey J Arbuck S Gwyther S Mooney M Rubinstein L Shankar L Dodd L Kaplan R Lacombe D & Verweij J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45(2) 228 - 247 2009. PMID: 19097774. DOI: 10.1016/j.ejca.2008.10.026
24 Wolmark N Wang J Mamounas E Bryant J & Fisher B Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. (30) 96 - 102 2001. PMID: 11773300. DOI: 10.1093/oxfordjournals.jncimonographs.a003469
25 Wolff AC Hammond ME Hicks DG Dowsett M McShane LM Allison KH Allred DC Bartlett JM Bilous M Fitzgibbons P Hanna W Jenkins RB Mangu PB Paik S Perez EA Press MF Spears PA Vance GH Viale G Hayes DF American Society of Clinical Oncology & College of American Pathologists Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 138(2) 241 - 256 2014. PMID: 24099077. DOI: 10.5858/arpa.2013-0953-SA
26 Kashiwagi S Asano Y Goto W Takada K Takahashi K Noda S Takashima T Onoda N Tomita S Ohsawa M Hirakawa K & Ohira M Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One. 12(2) e0170634 2017. PMID: 28166544. DOI: 10.1371/journal.pone.0170634
27 Hanahan D & Weinberg RA Hallmarks of cancer: the next generation. Cell. 144(5) 646 - 674 2011. PMID: 21376230. DOI: 10.1016/j.cell.2011.02.013
28 Dougan M & Dranoff G Immune therapy for cancer. Annu Rev Immunol. 27 83 - 117 2009. PMID: 19007331. DOI: 10.1146/annurev.immunol.021908.132544
29 Dunn GP Bruce AT Ikeda H Old LJ & Schreiber RD Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3(11) 991 - 998 2002. PMID: 12407406. DOI: 10.1038/ni1102-991
30 Dunn GP Old LJ & Schreiber RD The three Es of cancer immunoediting. Annu Rev Immunol. 22 329 - 360 2004. PMID: 15032581. DOI: 10.1146/annurev.immunol.22.012703.104803
31 Schreiber RD Old LJ & Smyth MJ Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 331(6024) 1565 - 1570 2011. PMID: 21436444. DOI: 10.1126/science.1203486
32 Burnet FM The concept of immunological surveillance. Prog Exp Tumor Res. 13 1 - 27 1970. PMID: 4921480. DOI: 10.1159/000386035
33 Brahmer JR Tykodi SS Chow LQ Hwu WJ Topalian SL Hwu P Drake CG Camacho LH Kauh J Odunsi K Pitot HC Hamid O Bhatia S Martins R Eaton K Chen S Salay TM Alaparthy S Grosso JF Korman AJ Parker SM Agrawal S Goldberg SM Pardoll DM Gupta A & Wigginton JM Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366(26) 2455 - 2465 2012. PMID: 22658128. DOI: 10.1056/NEJMoa1200694
34 Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF Powderly JD Carvajal RD Sosman JA Atkins MB Leming PD Spigel DR Antonia SJ Horn L Drake CG Pardoll DM Chen L Sharfman WH Anders RA Taube JM McMiller TL Xu H Korman AJ Jure-Kunkel M Agrawal S McDonald D Kollia GD Gupta A Wigginton JM & Sznol M Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366(26) 2443 - 2454 2012. PMID: 22658127. DOI: 10.1056/NEJMoa1200690
35 Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB Gonzalez R Robert C Schadendorf D Hassel JC Akerley W van den Eertwegh AJ Lutzky J Lorigan P Vaubel JM Linette GP Hogg D Ottensmeier CH Lebbé C Peschel C Quirt I Clark JI Wolchok JD Weber JS Tian J Yellin MJ Nichol GM Hoos A & Urba WJ Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363(8) 711 - 723 2010. PMID: 20525992. DOI: 10.1056/NEJMoa1003466
36 Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12(4) 252 - 264 2012. PMID: 22437870. DOI: 10.1038/nrc3239
37 Chen DS & Mellman I Oncology meets immunology: the cancer-immunity cycle. Immunity. 39(1) 1 - 10 2013. PMID: 23890059. DOI: 10.1016/j.immuni.2013.07.012